The prevalence and clinical characteristics of XXXX in @entity6 in Wisconsin.

@entity1 @entity851 @entity1593 @entity6 @entity294 @entity1467 @entity194 @entity490
BACKGROUND: The relationship between @entity1593 and @entity6 has long been known. Only a single study in the United States, from Buffalo, New York, has reported the prevalence of @entity1593 in a pediatric @entity6 population. This study was conducted to determine the prevalence and clinical presentation of @entity1593 in @entity1 and adolescents with @entity6 in Wisconsin, USA, using serum antiendomysial antibody as a screening test. METHODS: Two hundred eighteen @entity1 with @entity6 (113 males; age range, 4-21 years) and 117 age-and gender-matched control @entity1 were tested for immunoglobulin A endomysial antibody. Patients with positive results were offered a small bowel biopsy. A questionnaire regarding @entity490 , @entity294 , and @entity851 was completed by the parents. RESULTS: Seventeen of 218 @entity6 @entity1 (7.7%) had positive endomysial antibody. All control @entity1 had negative results for the endomysial antibody. Small bowel biopsy was performed in 14 @entity1 . Ten @entity1 had @entity194 . In one @entity1 without @entity194 , a repeat biopsy 2 years later showed @entity194 , and two @entity1 had increased intraepithelial lymphocytes without @entity194 . Seventy percent of the @entity1 with @entity1593 were asymptomatic. The reported symptoms were @entity490 and @entity294 (n = 1) and @entity851 (n = 2). Two @entity1 with @entity1593 had @entity1467 . CONCLUSIONS: The prevalence of @entity1593 in @entity1 with @entity6 in Wisconsin is at least 4.6%, which is comparable with European and Canadian studies. Because @entity1 without @entity194 may have @entity1593 , the prevalence may be even higher. All @entity1 with @entity6 should be screened for @entity1593 .
